JP5912126B2 - 医薬投与形態 - Google Patents
医薬投与形態 Download PDFInfo
- Publication number
- JP5912126B2 JP5912126B2 JP2013540480A JP2013540480A JP5912126B2 JP 5912126 B2 JP5912126 B2 JP 5912126B2 JP 2013540480 A JP2013540480 A JP 2013540480A JP 2013540480 A JP2013540480 A JP 2013540480A JP 5912126 B2 JP5912126 B2 JP 5912126B2
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- layer
- mucoadhesive
- pharmaceutical formulation
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002552 dosage form Substances 0.000 title claims description 57
- 229940079593 drug Drugs 0.000 claims description 105
- 239000003814 drug Substances 0.000 claims description 105
- 239000002121 nanofiber Substances 0.000 claims description 71
- 229920000642 polymer Polymers 0.000 claims description 68
- 239000013543 active substance Substances 0.000 claims description 65
- 239000012528 membrane Substances 0.000 claims description 56
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 55
- 230000003232 mucoadhesive effect Effects 0.000 claims description 50
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 39
- 238000001523 electrospinning Methods 0.000 claims description 35
- 238000004132 cross linking Methods 0.000 claims description 32
- 238000012377 drug delivery Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 238000010521 absorption reaction Methods 0.000 claims description 15
- 230000002496 gastric effect Effects 0.000 claims description 15
- 230000000968 intestinal effect Effects 0.000 claims description 15
- 239000001856 Ethyl cellulose Substances 0.000 claims description 12
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims description 12
- 210000002784 stomach Anatomy 0.000 claims description 11
- 229920001661 Chitosan Polymers 0.000 claims description 10
- 239000004952 Polyamide Substances 0.000 claims description 10
- 229920002647 polyamide Polymers 0.000 claims description 10
- 239000003658 microfiber Substances 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 229920002807 Thiomer Polymers 0.000 claims description 7
- -1 opioids Substances 0.000 claims description 7
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 6
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 229920001277 pectin Polymers 0.000 claims description 6
- 239000001814 pectin Substances 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 229920001610 polycaprolactone Polymers 0.000 claims description 5
- 239000004632 polycaprolactone Substances 0.000 claims description 5
- 229920006254 polymer film Polymers 0.000 claims description 5
- 210000005178 buccal mucosa Anatomy 0.000 claims description 4
- 230000007515 enzymatic degradation Effects 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- 229920000193 polymethacrylate Polymers 0.000 claims description 4
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 3
- 229940122361 Bisphosphonate Drugs 0.000 claims description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004150 aciclovir Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000001142 anti-diarrhea Effects 0.000 claims description 3
- 230000003474 anti-emetic effect Effects 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 229940125714 antidiarrheal agent Drugs 0.000 claims description 3
- 239000003793 antidiarrheal agent Substances 0.000 claims description 3
- 229940125683 antiemetic agent Drugs 0.000 claims description 3
- 239000002111 antiemetic agent Substances 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 239000003430 antimalarial agent Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940124522 antiretrovirals Drugs 0.000 claims description 3
- 239000003903 antiretrovirus agent Substances 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229960000794 baclofen Drugs 0.000 claims description 3
- 150000004663 bisphosphonates Chemical class 0.000 claims description 3
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 3
- 229960000830 captopril Drugs 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 229960003405 ciprofloxacin Drugs 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims description 3
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
- 229960003883 furosemide Drugs 0.000 claims description 3
- 229960002870 gabapentin Drugs 0.000 claims description 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 229960004502 levodopa Drugs 0.000 claims description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003105 metformin Drugs 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 229940005483 opioid analgesics Drugs 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 3
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 239000006041 probiotic Substances 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 235000018291 probiotics Nutrition 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000000825 pharmaceutical preparation Substances 0.000 claims 13
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
- 239000010410 layer Substances 0.000 description 63
- 210000004379 membrane Anatomy 0.000 description 55
- 239000000203 mixture Substances 0.000 description 45
- 238000009472 formulation Methods 0.000 description 43
- 239000000243 solution Substances 0.000 description 41
- 239000000835 fiber Substances 0.000 description 35
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 22
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 11
- 229960000520 diphenhydramine Drugs 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000004971 Cross linker Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 229920005597 polymer membrane Polymers 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- WMPOZLHMGVKUEJ-UHFFFAOYSA-N decanedioyl dichloride Chemical compound ClC(=O)CCCCCCCCC(Cl)=O WMPOZLHMGVKUEJ-UHFFFAOYSA-N 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 229910014033 C-OH Inorganic materials 0.000 description 3
- 229910014570 C—OH Inorganic materials 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000012867 bioactive agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229920005615 natural polymer Polymers 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013269 sustained drug release Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 101000807540 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 25 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102100037179 Ubiquitin carboxyl-terminal hydrolase 25 Human genes 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- PLMFYJJFUUUCRZ-UHFFFAOYSA-M decyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)C PLMFYJJFUUUCRZ-UHFFFAOYSA-M 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013266 extended drug release Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007925 in vitro drug release testing Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920000767 polyaniline Polymers 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940049413 rifampicin and isoniazid Drugs 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2010/03740 | 2010-11-26 | ||
| ZA201003740 | 2010-11-26 | ||
| PCT/IB2011/055331 WO2012070028A1 (en) | 2010-11-26 | 2011-11-28 | A pharmaceutical dosage form |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544259A JP2013544259A (ja) | 2013-12-12 |
| JP2013544259A5 JP2013544259A5 (cg-RX-API-DMAC7.html) | 2014-03-13 |
| JP5912126B2 true JP5912126B2 (ja) | 2016-04-27 |
Family
ID=46145444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540480A Active JP5912126B2 (ja) | 2010-11-26 | 2011-11-28 | 医薬投与形態 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9808418B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2646006B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5912126B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103338756B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012070028A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201304709B (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022014811A1 (ko) * | 2020-07-17 | 2022-01-20 | 엠엑스바이오 주식회사 | 의료용 나노 섬유 필름 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103611187A (zh) * | 2013-11-15 | 2014-03-05 | 无锡中科光远生物材料有限公司 | 一种时序性释放药物的组织工程支架的制备方法 |
| WO2015186108A1 (en) * | 2014-06-05 | 2015-12-10 | University Of The Witwatersrand, Johannesburg | 2 layers tablet oral dosage form for various drug release |
| CZ308594B6 (cs) * | 2014-09-29 | 2020-12-23 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Mukoadhezivní nosiče částic, způsob přípravy a použití |
| CN113197851A (zh) | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| CN108135835A (zh) | 2015-08-06 | 2018-06-08 | 约翰霍普金斯大学 | 用于治疗代谢紊乱的组合物和方法 |
| CN106822007B (zh) | 2015-09-11 | 2021-12-31 | 西姆莱斯股份公司 | 口服制剂 |
| US11129798B2 (en) * | 2016-08-19 | 2021-09-28 | Aron H. Blaesi | Fibrous dosage form |
| EP3407869A1 (en) * | 2016-01-27 | 2018-12-05 | Instar Technologies A.S. | Oromucosal nanofiber carriers for therapeutic treatment |
| JP7653218B2 (ja) | 2016-05-05 | 2025-03-28 | アクエスティブ セラピューティクス インコーポレイテッド | 送達増強エピネフリン組成物 |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| GB201614100D0 (en) * | 2016-08-17 | 2016-09-28 | Globalacorn Ltd | Carriers |
| RU2019125715A (ru) | 2017-01-23 | 2021-02-24 | Афикс Терапьютикс А/С | Способ изготовления двухслойного продукта на основе электроспряденных волокон |
| KR102595001B1 (ko) * | 2017-01-23 | 2023-10-26 | 에이에프와이엑스 테라퓨틱스 에스에이 | 높은 함량의 생체접착성 물질을 가지는 전기방사 섬유의 제조 방법 |
| CN107184560B (zh) * | 2017-06-03 | 2021-02-02 | 寿光富康制药有限公司 | 二甲双胍胃滞留片及制备方法 |
| WO2018226383A1 (en) * | 2017-06-07 | 2018-12-13 | Egy-Nano Pharma, Lp | Oral prolonged drug delivery platforms |
| WO2019067596A1 (en) * | 2017-09-26 | 2019-04-04 | Aquestive Therapeutics, Inc. | ADMINISTRATIVE PHARMACEUTICAL COMPOSITIONS CONTAINING PERMEATION PROMOTERS |
| GB2572566B (en) * | 2018-04-03 | 2022-01-12 | Zewail City Of Science And Tech | Wound healing system comprising layers of nanofiber matrices separately carrying a mucoadhesive, a drug and a moisture indicator, and use thereof |
| CN108589045B (zh) * | 2018-04-10 | 2021-06-08 | 华南理工大学 | 一种负载益生元和/或益生菌的纳米纤维膜及制备与应用 |
| JP7040418B2 (ja) * | 2018-11-21 | 2022-03-23 | 株式会社村田製作所 | 錠剤 |
| US12194294B2 (en) * | 2019-01-29 | 2025-01-14 | The Regents Of The University Of California | Oral drug delivery devices and methods using iontophoresis |
| CN109908108B (zh) * | 2019-03-15 | 2022-05-03 | 深圳市光远生物材料有限责任公司 | 一种载药纳米复合纤维膜系统及其制备方法和应用 |
| EP3968980A1 (en) | 2019-05-14 | 2022-03-23 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| EP4190551A1 (en) * | 2019-05-29 | 2023-06-07 | Mitsubishi Chemical Corporation | Method for using a nanomesh multilayer body |
| CN112107559B (zh) * | 2019-06-20 | 2023-09-08 | 普济生物科技（台州）有限公司 | 口腔透粘膜药物剂型 |
| CN110934894B (zh) * | 2019-12-09 | 2021-11-30 | 西南交通大学 | 一种载两歧双歧杆菌的抗肿瘤纤维局部埋植剂及其制备方法和应用 |
| AU2021214417B2 (en) * | 2020-01-31 | 2023-11-02 | Havas, Thomas Ernest ASSOC PROF | Drug delivery device |
| CN115843240A (zh) | 2020-05-11 | 2023-03-24 | 西姆莱斯股份公司 | 固体粘膜粘附组合物 |
| ES2876401B2 (es) * | 2020-05-11 | 2024-04-05 | Bioinicia S L | Parches auto-adhesivos de fibras para la liberación controlada de bioactivos |
| WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
| WO2022224464A1 (ja) * | 2021-04-21 | 2022-10-27 | 順也 藤森 | フィトケミカル組成物 |
| WO2023076281A1 (en) | 2021-10-25 | 2023-05-04 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
| CN114287634B (zh) | 2022-01-07 | 2022-08-19 | 东北农业大学 | 包埋益生菌的阿拉伯胶复合纤维/胶囊及其制备方法和应用 |
| CN116898826A (zh) * | 2023-07-12 | 2023-10-20 | 哈尔滨商业大学 | 一种胃滞留形状记忆复合膜的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE279914T1 (de) | 1998-11-27 | 2004-11-15 | Kanji Takada | Oral anzuwendendes arzneimittel zur wirkstoffverabreichung im magendarmtrakt |
| NZ519992A (en) | 2000-01-28 | 2004-04-30 | Smithkline Beecham Corp | Pharmaceutical compositions containing electrospun fiber of polymeric carrier integrated with active agent |
| ES2355233T3 (es) * | 2002-09-28 | 2011-03-24 | Mcneil-Ppc, Inc. | Formas de dosificación de liberación modificada con dos núcleos y una abertura. |
| BR0315194A (pt) | 2002-10-31 | 2005-08-23 | Umd Inc | Composições terapêuticas para liberação de droga para a, e através da, cobertura epitelial |
| JP5600005B2 (ja) * | 2007-09-05 | 2014-10-01 | 太陽化学株式会社 | 水溶性電界紡糸シート |
| ZA200903858B (en) * | 2008-06-19 | 2013-10-30 | Univ Of Witwatesrand Johannesburg | Pharmaceutical dosage form |
| US20110305768A1 (en) | 2008-07-01 | 2011-12-15 | The Johns Hopkins University | Quick-dissolving oral thin film for targeted delivery of therapeutic agents |
-
2011
- 2011-11-28 JP JP2013540480A patent/JP5912126B2/ja active Active
- 2011-11-28 WO PCT/IB2011/055331 patent/WO2012070028A1/en not_active Ceased
- 2011-11-28 US US13/988,959 patent/US9808418B2/en not_active Expired - Fee Related
- 2011-11-28 EP EP11842556.0A patent/EP2646006B1/en not_active Ceased
- 2011-11-28 CN CN201180066162.XA patent/CN103338756B/zh not_active Expired - Fee Related
-
2013
- 2013-06-24 ZA ZA2013/04709A patent/ZA201304709B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022014811A1 (ko) * | 2020-07-17 | 2022-01-20 | 엠엑스바이오 주식회사 | 의료용 나노 섬유 필름 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013544259A (ja) | 2013-12-12 |
| US20130337022A1 (en) | 2013-12-19 |
| EP2646006B1 (en) | 2015-02-25 |
| EP2646006A4 (en) | 2014-06-25 |
| US9808418B2 (en) | 2017-11-07 |
| CN103338756B (zh) | 2016-03-02 |
| EP2646006A1 (en) | 2013-10-09 |
| CN103338756A (zh) | 2013-10-02 |
| ZA201304709B (en) | 2015-03-25 |
| WO2012070028A1 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5912126B2 (ja) | 医薬投与形態 | |
| Sun et al. | pH-sensitive ZnO/carboxymethyl cellulose/chitosan bio-nanocomposite beads for colon-specific release of 5-fluorouracil | |
| Khutoryanskiy | Hydrogen-bonded interpolymer complexes as materials for pharmaceutical applications | |
| Chatterjee et al. | Stimuli-responsive hydrogels: An interdisciplinary overview | |
| Aduba Jr et al. | Semi-interpenetrating network (sIPN) gelatin nanofiber scaffolds for oral mucosal drug delivery | |
| Torres-Martínez et al. | Drugs loaded into electrospun polymeric nanofibers for delivery | |
| Kapahi et al. | Implication of nanofibers in oral drug delivery | |
| CN104136012A (zh) | 制备装载有活性物质的纳米颗粒的方法 | |
| JP2012503036A (ja) | ビニルアルコールコポリマークリオゲル、ビニルアルコールコポリマー並びにそれらの方法及び製品 | |
| Zhao et al. | Nanofiber orodispersible films based on carboxymethyl curdlan and PEO: New delivery system for amlodipine besylate | |
| CN101415442B (zh) | 控释凝胶 | |
| Raval et al. | Copolymers and block copolymers in drug delivery and therapy | |
| TWI619517B (zh) | 凝膠組成物及凝膠組成物的製造方法 | |
| Cheaburu-Yilmaz et al. | Polysaccharide containing gels for pharmaceutical applications | |
| CN108272770A (zh) | 层层自组装载双亲药物微胶囊及其制备方法 | |
| CN112107559A (zh) | 口腔透粘膜药物剂型 | |
| Shafi et al. | Optimizing the fabrication of electrospun nanofibers of prochlorperazine for enhanced dissolution and permeation properties | |
| Tyagi et al. | Electrospun nanofiber matrix with a mucoadhesive backing film for oramucosal drug delivery | |
| Mayur et al. | Super porous hydrogels: a recent advancement in gastroretentive drug delivery system | |
| Esuendale et al. | Cellulosic on transdermal drug delivery system: a review | |
| CN111643719A (zh) | 环γ-聚谷氨酸改性水凝胶负载纳米海绵解毒系统及其制备方法 | |
| Muniyandy et al. | Chitosan-sodium lauryl sulfate/Eudragit S100 beads loaded with 5-fluorouracil: Influence of solvent and duration of crosslinking the crosslinking on physicochemical properties | |
| CN105828812A (zh) | 胃内滞留口服药物组合物 | |
| Dumitriu et al. | A drug delivery system based on stimuli-responsive alginate/N-isopropylacryl amide hydrogel | |
| US20220287981A1 (en) | Adhesive drug delivery microparticles and a product comprising thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140124 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140919 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140924 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150421 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150717 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150831 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151020 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160112 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160315 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160331 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5912126 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |